Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||18 Years - 75 Years|
- - Signed informed consent, - Male or female patients, 18 to 75 years of age, - Confirmed clinico-pathological diagnosis of eosinophilic esophagitis (EoE) according to established diagnostic criteria - Clinico-pathological remission of EoE, - A documented trial with proton pump inhibitors (PPIs) in order to rule out PPI-responsive esophageal eosinophilia, - Negative pregnancy test in females of childbearing potential at baseline visit.
- - Clinical and endoscopic signs of gastroesophageal reflux disease (GERD), - History of abnormal results in case of an optionally performed pH-monitoring of the distal esophagus, - Patients with PPI-responsive esophageal eosinophilia - Achalasia, scleroderma esophagus, or systemic sclerosis, - Other clinically evident causes than EoE for esophageal eosinophilia, - Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection [candida esophagitis]), - Any relevant systemic disease (e.g., AIDS, active tuberculosis), - If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection, - Liver cirrhosis or portal hypertension, - History of cancer in the last five years, - History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit, - Upper gastrointestinal bleeding within 8 weeks prior to baseline visit, - Existing or intended pregnancy or breast-feeding.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|Dr. Falk Pharma GmbH|
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Ralph Mueller, PhD|
|Principal Investigator Affiliation||Dr. Falk Pharma GmbH|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Overall Status||Active, not recruiting|
The disease, disorder, syndrome, illness, or injury that is being studied.
Experimental: Budesonide 0.5mg orodispersible tablet twice daily
Budesonide 0.5mg orodispersible tablet twice daily
Experimental: Budesonide 1mg orodispersible tablet twice daily
Budesonide 1mg orodispersible tablet twice daily
Placebo Comparator: Placebo orodispersible tablet twice daily
Placebo orodispersible tablet twice daily
Drug: - Budesonide 0.5mg orodispersible tablet twice daily
Drug: - Budesonide 1mg orodispersible tablet twice daily
Drug: - Placebo orodispersible tablet twice daily
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Center for Digestive Diseases Eppendorf
Hamburg, , 20249